Low Perfusion Compartments in Glioblastoma Quantified by Advanced Magnetic Resonance Imaging and Correlated with Patient Survival
Overview
Authors
Affiliations
Background And Purpose: Glioblastoma exhibits profound intratumoral heterogeneity in perfusion. Particularly, low perfusion may induce treatment resistance. Thus, imaging approaches that define low perfusion compartments are crucial for clinical management.
Materials And Methods: A total of 112 newly diagnosed glioblastoma patients were prospectively recruited for maximal safe resection. The apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) were calculated from diffusion and perfusion imaging, respectively. Based on the overlapping regions of lowest rCBV quartile (rCBV) with the lowest ADC quartile (ADC) and highest ADC quartile (ADC) in each tumor, two low perfusion compartments (ADC-rCBV and ADC-rCBV) were identified for volumetric analysis. Lactate and macromolecule/lipid levels were determined from multivoxel MR spectroscopic imaging. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier's and multivariate Cox regression analyses, to evaluate the effects of compartment volume and lactate level on survival.
Results: Two compartments displayed higher lactate and macromolecule/lipid levels compared to contralateral normal-appearing white matter (each P < 0.001). The proportion of the ADC-rCBV compartment in the contrast-enhancing tumor was associated with a larger infiltration on FLAIR (P < 0.001, rho = 0.42). The minimally invasive phenotype displayed a lower proportion of the ADC-rCBV compartment than the localized (P = 0.031) and diffuse phenotypes (not significant). Multivariate Cox regression showed higher lactate level in the ADC-rCBV compartment was associated with worsened survival (PFS: HR 2.995, P = 0.047; OS: HR 4.974, P = 0.005).
Conclusions: Our results suggest that the ADC-rCBV compartment may potentially indicate a clinically measurable resistant compartment.
Complex Diagnostic Challenges in Glioblastoma: The Role of F-FDOPA PET Imaging.
Sipos D, Debreczeni-Mate Z, Ritter Z, Freihat O, Simon M, Kovacs A Pharmaceuticals (Basel). 2024; 17(9).
PMID: 39338377 PMC: 11434841. DOI: 10.3390/ph17091215.
Overcoming Barriers in Glioblastoma-Advances in Drug Delivery Strategies.
Ter Linden E, Abels E, van Solinge T, Neefjes J, Broekman M Cells. 2024; 13(12.
PMID: 38920629 PMC: 11201826. DOI: 10.3390/cells13120998.
Brain tumour microstructure is associated with post-surgical cognition.
Aznarez-Sanado M, Romero-Garcia R, Li C, Morris R, Price S, Manly T Sci Rep. 2024; 14(1):5646.
PMID: 38454017 PMC: 10920778. DOI: 10.1038/s41598-024-55130-5.
A novel approach for dose painting radiotherapy of brain metastases guided by mr perfusion images.
Hou C, Yin H, Gong G, Wang L, Su Y, Lu J Front Oncol. 2022; 12:828312.
PMID: 36531017 PMC: 9751668. DOI: 10.3389/fonc.2022.828312.
Visualising spatial heterogeneity in glioblastoma using imaging habitats.
Waqar M, van Houdt P, Hessen E, Li K, Zhu X, Jackson A Front Oncol. 2022; 12:1037896.
PMID: 36505856 PMC: 9731157. DOI: 10.3389/fonc.2022.1037896.